Search - tctmd.com

Displaying 1 - 20 of 358

Sort: Relevancy | Date

CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI

News Conference News AHA 2025

CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI

Michael O'Riordan

November 11, 2025

PROCTOR: PCI of Failed Bypass Grafts Tops Native-Vessel PCI, With Caveats

News Conference News TCT 2025

PROCTOR: PCI of Failed Bypass Grafts Tops Native-Vessel PCI, With Caveats

October 28, 2025

PARTNER 3 at 7 Years: Stable Outcomes, No Signs of Valve Failure With TAVI

News Conference News TCT 2025

PARTNER 3 at 7 Years: Stable Outcomes, No Signs of Valve Failure With TAVI

Michael O'Riordan

October 27, 2025

More Data on Tricuspid Valve Interventions Reassure, yet Questions Remain

News Conference News TCT 2025

More Data on Tricuspid Valve Interventions Reassure, yet Questions Remain

Yael L. Maxwell

October 26, 2025

SAVR Bests TAVI in Patients With Highly Calcific Aortic Valves

News Conference News EACTS 2025

SAVR Bests TAVI in Patients With Highly Calcific Aortic Valves

Yael L. Maxwell

October 20, 2025

DAPT’s Role After CABG Questioned: TACSI and TOP-CABG

News Conference News ESC 2025

DAPT’s Role After CABG Questioned: TACSI and TOP-CABG

September 05, 2025

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

News Conference News ESC 2025

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Michael O'Riordan

September 04, 2025

ESC/EACTS Release New Valvular Heart Disease Guidelines

News Conference News ESC 2025

ESC/EACTS Release New Valvular Heart Disease Guidelines

Yael L. Maxwell

September 03, 2025

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

News Conference News ESC 2025

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

September 01, 2025

No Benefit to Routine CT Angiography After Left Main PCI: PULSE

News Conference News ESC 2025

No Benefit to Routine CT Angiography After Left Main PCI: PULSE

Michael O'Riordan

August 31, 2025

Global Burden of Degenerative Mitral Valve Disease Continues to Rise

News Conference News NY Valves 2025

Global Burden of Degenerative Mitral Valve Disease Continues to Rise

June 30, 2025

Good Outcomes, Little Hospital Experience: Pascal TEER in Real World

News Conference News NY Valves 2025

Good Outcomes, Little Hospital Experience: Pascal TEER in Real World

Yael L. Maxwell

June 30, 2025

Prompt TAVI Benefits Asymptomatic AS Patients Regardless of Guideline Indication

News Conference News NY Valves 2025

Prompt TAVI Benefits Asymptomatic AS Patients Regardless of Guideline Indication

June 27, 2025

OCT-Guided PCI Bests Angiography in ACS Patients: OCCUPI

News Conference News EuroPCR 2025

OCT-Guided PCI Bests Angiography in ACS Patients: OCCUPI

May 28, 2025

Stroke Risk Higher With TAVI vs Surgery at 5 Years: UK TAVI

News Conference News EuroPCR 2025

Stroke Risk Higher With TAVI vs Surgery at 5 Years: UK TAVI

Michael O'Riordan

May 23, 2025

Obesity-Related Cancer Rates No Different With GLP-1s vs Bariatric Surgery

News Conference News European Congress on Obesity 2025

Obesity-Related Cancer Rates No Different With GLP-1s vs Bariatric Surgery

Michael O'Riordan

May 14, 2025

Medicare Analysis Reassures on PCI in Ambulatory Surgery Centers

News Conference News SCAI 2025

Medicare Analysis Reassures on PCI in Ambulatory Surgery Centers

May 07, 2025

BATMAN Signals New Way to Prevent LVOT Obstruction in High-Risk TMVR Patients

News Conference News SCAI 2025

BATMAN Signals New Way to Prevent LVOT Obstruction in High-Risk TMVR Patients

May 07, 2025

More Patient-Prosthesis Mismatch With TAVI in Women, but 5-Year Survival Unaffected

News Conference News SCAI 2025

More Patient-Prosthesis Mismatch With TAVI in Women, but 5-Year Survival Unaffected

May 02, 2025

Cost Surprises and Delayed Care in Women: BASIL-2 and BEST-CLI

News Conference News CX Symposium 2025

Cost Surprises and Delayed Care in Women: BASIL-2 and BEST-CLI

April 30, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.